Document is current
Any future updates will be listed below
-
Authors
Huang, Daniel Q. https://orcid.org/0000-0002-5165-5061
Wong, Vincent W. S. https://orcid.org/0000-0003-2215-9410
Rinella, Mary E. https://orcid.org/0000-0003-0620-9705
Boursier, Jerome
Lazarus, Jeffrey V. https://orcid.org/0000-0001-9618-2299
Yki-Järvinen, Hannele
Loomba, Rohit https://orcid.org/0000-0002-4845-9991
- License Information
-
More Information
Article History
Accepted: 7 February 2025
First Online: 6 March 2025
Competing interests
: D.Q.H. has served as an advisory board member for Gilead and Roche. V.W.S.W. has served as a consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions and Visirna, and as a speaker for Abbott, AbbVie, Echosens, Gilead Sciences, Novo Nordisk and Unilab. He has also received a research grant from Gilead Sciences and is a co-founder of Illuminatio Medical Technology. M.E.R. serves as a consultant for 89Bio, Akero, Boehringer Ingelheim, Cytodyn, Echosens, GSK, Histoindex, Eli Lilly, Madrigal, Novo Nordisk, Sagimet, Sonic Incytes and Takeda. J.B. serves as a consultant to Echosens, Inventiva and Novo Nordisk. In addition, his institutions received research grants from Diafir, Echosens, Gilead, Intercept, Inventiva, Ipsen and Siemens. J.V.L. acknowledges grants to ISGlobal from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal, MSD, Novo Nordisk, Pfizer and Roche Diagnostics, consulting fees from Echosens, GSK, Novo Nordisk, Pfizer and Roche Diagnostics, and payment or honoraria for lectures from AbbVie, Echosens, Gilead Sciences, GSK, Janssen, MSD, Novo Nordisk and Pfizer, outside of the submitted work. J.V.L. further acknowledges support to ISGlobal from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Programme. R.L. serves as a consultant for Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89bio, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. He is also a co-founder of LipoNexus Inc. All other authors declare no competing interests.
